Pediatric Advisory Committee To Review Postmarketing Safety Data For 16 Products
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee will examine QT prolongation signal seen in safety review of Forest’s Celexa.
You may also be interested in...
Tamiflu U.S. Labeling Adopts Japanese Warnings
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.